Hyaluronidase reduces human breast cancer xenografts in SCID mice

International Journal of Cancer

Volumn 102, Issue 2, 2002, Pages 192-197

  Shuster, Svetlana ^a   Frost, Gregory I ^b   Csoka, Antonei B ^a   Formby, Bent ^c   Stern, Robert ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c Rasmus Institute for Medical Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cancer xenografts; CD44; Extracellular matrix; Hyaluronan; Hyaluronidase; SCID mice

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; HYALURONIDASE; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRAFT; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTIGENS, CD44; FEMALE; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037058318     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10668     Document Type: Article

References (65)

1. Toole BP. Proteoglycans and hyaluronan in morphogenesis and differentiation. In: Hay ED, ed. Cell biology of the extracellular matrix, 2nd ed. New York: Plenum Press, 1991, 259-94.
2. Zhang L, Underhill CB, Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 1995;55:428-33.
3. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000;156:529-36.
4. Pawlowski A, Haberman HF, Menon IA. The effects of hyaluronidase upon tumor formation in BALB/c mice painted with 7,12-dimethylbenz-(a)anthracene. Int J Cancer 1979;23:105-9.
5. De Maeyer E, De Maeyer-Guignard J. The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and polymorphism. Int J Cancer 1992;51:657-60.
6. Bourguignon LYW, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 1998;3:637-49.
7. Entwistle J, Hall CL, Turley EA. HA receptors: regulators of signaling to the cytoskeleton. J Cell Biochem 1996;61:569-77.
8. Bourguignon LY, Zhu H, Shao L, Chen, YW. CD44 interaction with tiaml promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem 2000;275:1829-38.
9. Underhill C. CD44: the hyaluronan receptor. J Cell Sci 1992;103:293-8.
10. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-4.
11. Jackson DG, Buckley J, Bell JI. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 1992;267:4732-9.
12. Lewin D. New reports blur image of promising metastasis marker. J NIH Res 1996;8:24-6.
13. Tanabe KK, Nishi T, Saya H. Novel variants of CD44 arising from alternative splicing: changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Mol Carcinog 1993;7:212-20.
14. Stern R, Shuster S, Wiley TS, Formby B. Hyaluronidase can modulate expression of CD44. Exp Cell Res 2001;266:167-76.
15. Guntenhoener MW, Pogrel MA, Stern R. A substrate-gel assay for hyaluronidase activity. Matrix Biol 1992;12:388-96.
16. Cherr GN, Meyers SA, Yudin AI, VandeVoort CA, Myles DG, Primakoff P, Overstreet JW. The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity. Dev Biol 1996;175:142-53.
17. Meyer MF, Kreil G, Aschauer H. The soluble hyaluronidase from bull testes is a fragment of the membrane-bound PH-20 enzyme. FEBS Lett 1997;413:385-8.
18. Tolksdorf S, McCready MH, McCullagh DR, Schwenk E. The turbidimetric assay of hyaluronidase. J Lab Clin Med 1949;34:74-9.
19. Frost GI, Stern R. A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. Anal Biochem 1997;251:263-9.
20. Tengblad A. Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding properties from cartilage. Biochim Biophys Acta 1979;578:281-9.
21. Lin W, Shuster S, Maibach HI, Stern R. Patterns of hyaluronan staining are modified by fixation techniques. J Histochem Cytochem 1997;45:1157-63.
22. Culty M, Shizari M, Thompson EW, Underhill CB. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol 1994;160:275-86.
23. Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992;6:2397-404.
24. Delpech B, Girard N, Bertrand P, Courel MN, Chauzy C, Delpech A. Hyaluronan: fundamental principles and applications in cancer. J Intern Med 1997;242:41-8.
25. Kosaki R, Watanabe K, Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 1999;59:1141-5.
26. Knudson W. The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue. Front Biosci 1998;3:604-15.
27. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
28. Kujawa MJ, Pechak DG, Fiszman MY, Caplan AI. Hyaluronic acid bonded to cell culture surfaces inhibits the program of myogenesis. Dev Biol 1986;113:10-6.
29. Knudson W, Bartnik E, Knudson CB. Assembly of pericellular matrices by COS-7 cells transfected with CD44 lymphocyte-homing receptor genes. Proc Natl Acad Sci USA 1993;90:4003-7.
30. Knudson CB. Hyaluronan receptor-directed assembly of chondrocyte pericellular matrix. J Cell Biol 1993;120:825-34.
31. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, Cardiff RD. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998;176:206-15.
32. Kalish, ED, Iida N, Moffat FL, Bourguignon LY. A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression. Front Biosci 1999;4:1-8.
33. Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E. Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res 1995;281:317-24.
34. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
35. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997;186:1985-96.
36. Henke C, Bitterman P, Roongta U, Ingbar D, Polunovsky V. Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease. Am J Pathol 1996;149:1639-50.
37. Seoh JY, Woo SY, Im SA, Kim YJ, Park, HY, Lee S. Distinct patterns of apoptosis in association with modulation of CD44 induced by thrombopoietin and granulocyte-colony stimulating factor during ex vivo expansion of human cord blood CD34+ cells. Br J Haematol 1999;107:176-85.
38. Kaneko T, Saito H, Toya M, Satio T, Nakahara K, Hiroi M. Hyaluronic acid inhibits apoptosis in granulosa cells via CD44. J Assist Reprod Gen 2000;17:162-7.
39. Tian B, Takasu T, Henke C. Functional role of cyclin A on induction of fibroblast apoptosis due to ligation of CD44 matrix receptor by anti-CD44 antibody. Exp Cell Res 2000;257:135-44.
40. McBride WH, Bard JB. Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med 1979;149:507-15.
41. Delmage JM, Powars DR, Jaynes PK, Allerton SE. The selective suppression of immunogenicity by hyaluronic acid. Ann Clin Lab Sci 1986;16:303-10.
42. Collis L, Hall C, Lange L, Ziebell M, Prestwich R, Turley EA. Rapid hyaluronan uptake is associated with enhanced motility: implications for an intracellular mode of action. FEBS Lett 1998;440:444-9.
43. Evanko SP, Wight TN. Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem 1999;47:1331-42.
44. Furukawa K, Terayama H. Isolation and identification of glycosaminoglycans associated with purified nuclei from rat liver. Biochim Biophys Acta 1977;499:278-89.
45. Eggli PS, Graber W. Association of hyaluronan with rat vascular endothelial and smooth muscle cells. J Histochem Cytochem 1995;43:689-97.
46. Grammatikakis N, Grammatikakis A, Yoneda M, Yu Q, Banerjee SD, Toole BP. A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein, Cdc37. J Biol Chem 1995;270:16198-205.
47. Deb TB, Datta K. Molecular cloning of human fibroblast hyaluronic acid-binding protein confirms its identity with P-32, a protein copurified with splicing factor SF2. J Biol Chem 1996;271:2206-12.
48. Beckenlehner K, Bannke S, Spruss T, Bernhardt G, Schonenberger H, Schiess W. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol 1992;118:591-6.
49. Spruss T, Bernhardt G, Schonenberger H, Schiess W. Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol 1995;121:193-202.
50. Baumgartner G, Gomar-Hoss C, Sakr L, Ulsperger E, Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors-experimental clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998;131:85-99.
51. Brekken C, Bruland OS, de Lange Davies C. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res 2000;20:3503-12.
52. Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol 1995;154:5345-55.
53. Chang NS. Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int J Mol Med 1998;2:653-9.
54. St. Croix B, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst 1996;88:1285-96.
55. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001;20:499-508.
56. Lepperdinger G, Mullegger J, Kreil G. Hyal2-less active, but more versatile? Matrix Biol 2001;20:509-14.
57. Cherr GN, Yudin AI, Overstreet JW. The dual functions of GPI-anchored PH-20: hyaluronidase and intracellular signaling. Matrix Biol 2001;20:515-25.
58. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60:6116-33.
59. Sekido Y, Ahmadian M, Wistuba I, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998;16:3151-7.
60. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez P, Piris MA. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999;154:1583-9.
61. Edelson MI, Scherer SW, Tsui, LC Welch, WR, Bell DA, Berkowitz RS, Mok SC. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 1997;14:2979-84.
62. Karjalainen JM, Tammi RH, Tammi MI., Eskelinen MJ, Agren UM, Parkkinen JJ, Alhava EM, Kosma VM. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 2000;157:957-65.
63. Pham HT, Block NL, Lokeshwar, VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83.
64. Madan AK, Pang Y, Wilkiemeyer MB, Yu D, Beech DJ. Increased hyaluronidase expression in more aggressive prostate adenocarcinoma. Oncol Rep 1999;6:1431-3.
65. Bertrand P, Girard N, Duval C, d'Anjou J, Chauzy C, Menard JF, Delpech B. Increased hyaluronidase levels in breast tumor metastases. Int J Cancer 1997;73:327-31.